Objective: To determine an appropriate age threshold at which to prescribe aspirin for primary cardiovascular disease (CVD) prevention among men and women without diabetes.
Design: Cross-sectional study.
Setting: 304 general practices in England and Wales contributing to The Health Improvement Network (THIN) electronic patient files.
Participants: Subjects aged between 30 and 75 years without diabetes, not prescribed any lipid-lowering treatment and with no previous history of CVD. Subjects had to have been registered by their practices for the whole of the preceding 12 months to be included in the analysis.
Outcomes measures: Relation between age and coronary heart disease (CHD) risk, and the age threshold at which subjects without diabetes develop an estimated 10-year CHD risk of ⩾10%.
Results: The age transition from <10% to >10%, 10-year CHD risk for men and women without diabetes occurred at ages 47.8 for men and 57.3 for women.
Conclusions: In the absence of significant bleeding risks, aspirin should routinely be considered for all men and women without diabetes above the ages of 48 and 57 years, respectively, for primary CVD prevention. For subjects below these age thresholds or for those above the age of 75 years, the decision to initiate aspirin should be based on a patient’s individual cardiovascular risk profiles. These proposed age thresholds aim to take into account a patient’s gender, bleeding risk and the cardioprotective benefits of low-dose aspirin treatment.
Statistics from Altmetric.com
Competing interests: None.
UB and SS were involved in study design and data acquisition, DJF was involved in the study coordination and data interpretation. JS was involved in the study design, led the study analysis and participated in data interpretation. II conceived the study, participated in its design and analysis and led the study coordination, data interpretation and drafting of the manuscript. All authors read, contributed towards and approved the final manuscript. II is the guarantor.
See Editorial, p 1364
Ethics approval: Approved by the Eastern Multi Centre Research Ethics Committee.